Total Raised

$90.01M

Investors Count

12

Deal Terms

5

Funding, Valuation & Revenue

12 Fundings

RedShift BioAnalytics has raised $90.01M over 12 rounds.

RedShift BioAnalytics's latest funding round was a Series F - II for $5.91M on June 25, 2025.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

6/25/2025

Series F - II

$5.91M

$XXM

0

FY undefined

1

4/2/2024

Series F

$5M

$XXM

0

FY undefined

1

10/18/2021

Series E

$20M

$XXM

0

FY undefined

3

12/23/2020

Series D - II

$XXM

$XXM

0

FY undefined

10

4/12/2020

Loan

$XXM

$XXM

0

FY undefined

0

Date

6/25/2025

4/2/2024

10/18/2021

12/23/2020

4/12/2020

Round

Series F - II

Series F

Series E

Series D - II

Loan

Amount

$5.91M

$5M

$20M

$XXM

$XXM

Investors

Valuation

$XXM

$XXM

$XXM

$XXM

$XXM

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

1

3

10

0

Start free trial
New call-to-action

RedShift BioAnalytics Deal Terms

5 Deal Terms

RedShift BioAnalytics's deal structure is available for 5 funding rounds, including their Series C from March 14, 2017.

Round

Series C

Unattributed

Series B

Series A - II

Series A

Funding Date

$XXM

$XXM

$XXM

$XXM

$XXM

Pre-Money Valuation

$XXM

$XXM

$XXM

$XXM

Post-Money Valuation

$XXM

$XXM

$XXM

$XXM

Amount Raised

$XXM

$XXM

$XXM

$XXM

$XXM

Shares Authorized

Issuance Price

$XXM

$XXM

$XXM

$XXM

Dividend Rate

$XXM

$XXM

$XXM

Liquidation Preferences

$XXM

$XXM

$XXM

$XXM

Liquidation Price

Participation

$XXM

Conversion Price

Anti Dilution

$XXM

$XXM

$XXM

$XXM

General Voting

$XXM

$XXM

$XXM

$XXM

$XXM

Board Voting

$XXM

$XXM

$XXM

$XXM

$XXM

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series C

$XXM

$XXM

$XXM

$XXM

Unattributed

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

Series B

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

Series A - II

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

Series A

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

RedShift BioAnalytics Investors

12 Investors

RedShift BioAnalytics has 12 investors. Technology Venture Partners invested in RedShift BioAnalytics's Series F - II funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

1/23/2006

6/25/2025

9
Series A, Series A - II (2009), Series B (2013), Series C (2017), Series D (2018), Series D - II (2020), Series E (2021), Series F (2024), Series F - II (2025)

Venture Capital

Minnesota

10/18/2021

6/25/2025

2
Series E, Series F - II (2025)

Venture Capital

California

4/2/2024

6/25/2025

2
Series F, Series F - II (2025)

Venture Capital

Minnesota

00/00/0000

00/00/0000

Waters

Subscribe to see more

Corporation

Massachusetts

00/00/0000

00/00/0000

Mutual Capital Partners

Subscribe to see more

Venture Capital

Ohio

First funding

1/23/2006

10/18/2021

4/2/2024

00/00/0000

00/00/0000

Last Funding

6/25/2025

6/25/2025

6/25/2025

00/00/0000

00/00/0000

Investor

Waters

Mutual Capital Partners

Rounds

9
Series A, Series A - II (2009), Series B (2013), Series C (2017), Series D (2018), Series D - II (2020), Series E (2021), Series F (2024), Series F - II (2025)
2
Series E, Series F - II (2025)
2
Series F, Series F - II (2025)

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Venture Capital

Venture Capital

Corporation

Venture Capital

Location

Minnesota

California

Minnesota

Massachusetts

Ohio

New call-to-action

Compare RedShift BioAnalytics to Competitors

A
Applied Isotope Technologies

Applied Isotope Technologies provides measurement solutions for elemental, speciated, and molecular analysis across various sectors. The services offered include biomarker analysis, environmental toxin detection, food and supplement analysis, fossil fuel testing, neuropeptide quantification, and exposomics research. The company serves sectors requiring precise and legally defensible data for research and regulatory purposes. It was founded in 2003 and is based in Pittsburgh, Pennsylvania.

Evolutionary Genomics Logo
Evolutionary Genomics

Evolutionary Genomics operates in the biotechnology sector, focusing on plant genetic enhancement. The company develops and patents genes that confer resistance to pests and diseases, enhance sweetness, and improve yield in various crops. It was founded in 2000 and is based in Longmont, Colorado.

S
Solecta

Solecta specializes in membrane separation solutions within the industrial sector. The company offers polymeric membranes for microfiltration, ultrafiltration, nanofiltration, and reverse osmosis. Solecta primarily serves sectors such as food, dairy, life sciences, and manufacturing industries. It was founded in 1998 and is based in Oceanside, California.

N
Nano Carrier

Nano Carrier is a biotech company using nanotechnology to improve patient Quality of Life with a focus on cancer.

J
J. Lamarck

J. Lamarck is a company that offers advisory services to private individuals, companies and pension funds who want to invest in the biotechnology sector.nThe company offers a high quality service and its analyst provide professional assistance to people who want to diversify a part of their portfolio in this emerging industry. Because of the nature of biotechnology investments, the company believe it is important that users work with specialists to define their portfolio strategy. Generally, specialists do things better.nOver the next few years the company will be witness of astonishing progress in health care and medicine, the company will be able to fight and cure diseases like AIDS and cancer finally. The company will also find solutions to clean up the environment and new crops that don't need pesticide. These new products will obviously boost the visibility of the companies that were at the beginning of this process on the stock market and consequently create great opportunity for it's shareholders.nJ. Lamarck wants to be their partner in this great venture.

Fluidic Analytics Logo
Fluidic Analytics

Fluidic Analytics conducts protein interaction analysis and biomolecular characterization within the life sciences sector. The company provides tools and technologies for measuring protein interactions and characteristics in solution, related to drug discovery and disease diagnosis. Fluidic Analytics serves sectors engaged in biological research and clinical diagnostics. It was founded in 2013 and is based in Royston, England.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.